‘Medical Cannabis Cost My Brother Everything’: The Oliver Robinson Case Explained

This revised report presents the key developments behind ‘Medical Cannabis Cost My Brother Everything’: The Oliver Robinson Case Explained in a clearer structure, without adding claims beyond the original article.

The death of 34-year-old Oliver Robinson from Bury prompted renewed questions in 2026 about how medical cannabis is prescribed to people with complex mental-health and addiction histories. His brother Alexander launched a campaign calling for tighter safeguards after an inquest examined Oliver’s final years. The case is important because it sits at the intersection of patient choice, private prescribing, mental-health risk and a medicine that can help some people while creating serious problems for others.

Reporting on the case should avoid two extremes. It would be wrong to suggest that all medical cannabis is inherently dangerous or that Oliver’s death can be reduced to one cause. It would also be wrong to ignore the concerns raised by his family and the coroner about dependence, psychiatric illness and the way prescription status can affect a patient’s perception of risk. The inquest considered multiple contributing factors, and the private clinic involved said its prescribing decisions were made through a multidisciplinary process and informed by evidence.

What Oliver Robinson’s family said

Alexander Robinson described his younger brother as sociable, creative and generous, but also said Oliver had struggled for years with depression and addiction. He had previously sought treatment, including admissions to the Priory. According to the family, Oliver later became convinced that medicinal cannabis was the answer to his difficulties and increasingly resisted alternatives that did not involve cannabis.

The family’s concern was not simply that a prescription existed. They believed the medical framing gave Oliver a sense that his cannabis use was unquestionably therapeutic even as his mental health and relationships deteriorated. Alexander said the family saw aggression, threats, financial problems and worsening dependence during this period.

The inquest did not identify a single simple cause

Oliver died in November 2023. The inquest that concluded in 2026 considered a range of factors around his death, including mental-health difficulties, housing conflict, debt and his relationship with cannabis. Reporting of the findings said the coroner concluded that Oliver had refused psychiatric and addiction help because of his commitment to prescription cannabis.

It is important not to rewrite that finding as a claim that medical cannabis alone caused his death. Inquests often examine overlapping circumstances rather than a single isolated event. The family’s campaign is based on the view that prescribing safeguards were inadequate for someone with Oliver’s vulnerabilities, not on a claim that every patient will respond in the same way.

Why psychiatric history matters when THC is involved

The NHS says cannabis products containing THC can carry mental-health risks. Regular cannabis use can increase the risk of psychotic illness in some people, and dependence can occur. The NHS also notes that risk tends to increase as THC exposure increases. That does not mean every patient prescribed a THC-containing product will experience psychosis or dependence, but it does mean clinicians need to consider individual vulnerability.

People with previous psychosis, severe mood disorders, substance-use problems or a family history of certain psychiatric conditions may require particularly careful assessment and monitoring. A medicine can have a legitimate therapeutic role for one patient and still be unsuitable for another.

Medical cannabis has been legal on prescription since 2018

UK rules changed in November 2018 so that certain cannabis-based products for medicinal use could be prescribed in controlled circumstances. The legal change did not make recreational cannabis lawful. It created a medical route under which appropriately authorised clinicians can prescribe qualifying products.

Government guidance originally restricted prescribing of unlicensed cannabis-based medicinal products to doctors on the General Medical Council specialist register. Most cannabis-based products remain unlicensed medicines, meaning they have not gone through the same marketing-authorisation process as standard licensed medicines for every indication in which they may be used.

Why private prescribing has become part of the debate

NHS access to cannabis-based medicines has remained limited to specific circumstances, while private clinics have become an important route for some patients. That has created a policy question: how should regulators balance access for people who say conventional treatments failed with the need for consistent screening, informed consent and follow-up?

The Robinson case brought particular attention to patients with complex mental-health histories. A clinic may believe that treatment is clinically justified, while relatives may observe deterioration outside appointments. Good governance therefore depends not only on the original prescription but also on monitoring, communication and willingness to reconsider treatment if risks change.

What the clinic said

The private provider involved in Oliver’s care said prescribing decisions were made by a multidisciplinary team and based on the available evidence. That response matters because the case should not be reported as though the family’s account is the only perspective. The central dispute is about whether the safeguards and clinical judgments were sufficient for Oliver’s circumstances.

Without access to a patient’s full records, outside readers cannot reconstruct every clinical decision. The case instead raises a broader systems question about what information should trigger extra caution, how often reviews should occur and how clinicians should respond when a patient’s family reports severe behavioural change.

Prescription does not mean risk-free

Patients often assume that ‘medical’ and ‘safe’ mean the same thing. In reality, every effective medicine can have adverse effects, contraindications and interactions. Prescription status means a clinician has judged that the potential benefits justify the risks for a particular patient; it does not guarantee that the treatment will remain suitable indefinitely.

That distinction is especially important for medicines that affect mood, perception, sleep or cognition. Patients and families need clear information about warning signs and a route back to the prescriber if problems emerge.

Dependence and tolerance are different but related ideas

Tolerance means a person may need a larger amount of a substance to achieve the same effect. Dependence means the body or mind has adapted to regular use so that stopping or reducing can be difficult. Neither concept automatically implies reckless behaviour, and neither is unique to cannabis.

The NHS describes dependency as a potential risk with THC-containing medical cannabis, although it notes that controlled specialist use may reduce that risk. For patients with a previous addiction history, the possibility of problematic use is particularly relevant to assessment and follow-up.

Why evidence varies by medical condition

Public discussion sometimes treats ‘medical cannabis’ as one treatment for dozens of unrelated conditions. In practice, cannabis-based products differ in THC and CBD content, formulation and dose, while evidence differs sharply by indication. Some licensed cannabis-based medicines have established roles in specific conditions, whereas evidence for other uses is limited or uncertain.

This is why the phrase ‘it works’ or ‘it does not work’ is too broad. A product that helps one symptom in one patient group may have no proven benefit for another condition and may carry different risks depending on the person.

The role of the Advisory Council review

The Advisory Council on the Misuse of Drugs launched a review of the impact of the 2018 legal changes, including intended benefits and unintended consequences. Its call for evidence sought input from clinicians, researchers, patients, families, industry and regulators. That process reflects the fact that the medical-cannabis system is still evolving.

Cases such as Oliver Robinson’s do not by themselves determine national policy, but they can identify areas regulators may want to examine: psychiatric screening, advertising, follow-up, prescribing thresholds and communication between private providers and NHS services.

Questions patients can raise with a prescriber

• What specific symptom or condition is this treatment intended to improve?
• What evidence supports its use for my diagnosis?
• How much THC and CBD does the product contain?
• What mental-health or dependency risks are relevant to my history?
• What side effects should lead me to contact the clinic urgently?
• How often will the treatment be reviewed?
• What alternatives are available if it does not help or makes symptoms worse?
• How will my other medicines and healthcare providers be involved?

What families can do when they are worried

Relatives cannot always override an adult patient’s medical choices, but they can document changes and encourage the person to speak to the prescriber or GP. Sudden paranoia, severe agitation, hallucinations, threats of violence, suicidal thoughts or an inability to function normally warrant urgent professional assessment.

In an immediate emergency, families should use emergency services rather than relying on a routine clinic appointment. If the concern is not immediate, contacting the prescribing service, GP or mental-health team can help create a record of what has been observed.

Frequently asked questions

Is medical cannabis legal in the UK?

Yes, qualifying cannabis-based products can be prescribed in controlled circumstances. Recreational cannabis remains illegal.

Can THC worsen mental-health problems?

The NHS says THC-containing cannabis products can increase the risk of psychosis in some people and can lead to dependency. Risk varies by product, dose and individual vulnerability.

Did the coroner say cannabis was the only cause of Oliver Robinson’s death?

No. Reporting of the inquest described multiple contributing factors. The family’s campaign focuses on whether prescribing safeguards were sufficient given his psychiatric and addiction history.

Should a patient stop prescribed cannabis suddenly?

Medication changes should normally be discussed with the prescriber, unless emergency clinicians advise otherwise. Sudden changes can create their own problems.

Conclusion

Oliver Robinson’s case is a difficult reminder that legal access to a medicine does not eliminate the need for careful patient selection and follow-up. His family believes medicinal cannabis reinforced a harmful pattern and prevented him from engaging with other treatment. The clinic involved has said its prescribing process used multidisciplinary review and evidence-based decision-making. Those positions should both be represented when the case is discussed.

The broader lesson is not that medical cannabis should be celebrated or condemned in absolute terms. It is that benefits and risks depend on the patient, the product, the indication and the quality of monitoring. For people with complex mental-health and addiction histories, that assessment may need to be especially cautious and responsive to changes over time.